UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
To Section 13 or 15(d) Of the Securities and Exchange Act Of
1934
August
6,
2008
Date
of
Report (Date of earliest event reported)
WATSON
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Nevada
|
001-13305
|
95-3872914
|
(State
or other Jurisdiction
of
Incorporation)
|
(Commission
File Number)
|
(IRS
Employer
Identification
Number)
|
311
Bonnie Circle
Corona,
California
(Address
of principal executive offices)
|
|
92880
(Zip
Code)
|
(951)
493-5300
(Registrant’s
telephone number, including area code)
N/A
(Former
Name or Former Address, if Changed Since Last Report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
|
|
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
|
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
Item
2.02 Results
of Operations and Financial Condition.
On
August
6,
2008,
Watson
Pharmaceuticals, Inc. (the “Company”) issued a press release reporting the
financial results of the Company for the second
quarter ended June 30, 2008.
A copy
of the Company’s press release is attached to this report as Exhibit 99.1 and
incorporated herein by reference.
In
its
press release, the Company included non-GAAP financial measures, as defined
in
Regulation G promulgated by the U. S. Securities and Exchange Commission. The
Company believes that its inclusion of non-GAAP financial measures provides
useful supplementary information to and facilitates analysis by investors in
evaluating the Company’s performance and trends. The Company uses both GAAP
financial measures and the disclosed non-GAAP financial measures internally
to
evaluate and manage the Company’s operations and to better understand its
business. These non-GAAP financial measures are in addition to, not a substitute
for, or superior to, measures of financial performance prepared in accordance
with GAAP.
The
information in this report (including the exhibit) is furnished pursuant to
Item
2.02 and shall not be deemed to be “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934 (the “Exchange Act”), nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933 or
the
Exchange Act, except as shall be expressly set forth by specific reference
in
such filing.
Item
9.01 Financial
Statements and Exhibits.
d.
Exhibits:
|
99.1
|
Press
Release titled “Watson Pharmaceuticals Reports Second
Quarter 2008
Results” dated August
6, 2008.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated:
August
6, 2008
|
WATSON
PHARMACEUTICALS, INC.
|
|
|
|
|
By:
|
/s/
Mark
W. Durand
|
|
|
Mark
W. Durand
|
|
|
Senior
Vice
President - Chief
Financial Officer
|
|
|
Principal
Financial Officer
|
EXHIBIT
INDEX
Exhibit
No.
|
|
Description
|
99.1
|
|
Press
Release titled “Watson Pharmaceuticals Reports Second
Quarter 2008
Results” dated August
6,
2008.
|